Immunotherapy in association with stereotactic radiotherapy for non-small cell lung cancer brain metastases: results from a multicentric retrospective study on behalf of AIRO.
brain metastases
immunotherapy
non-small cell lung cancer
radiosurgery
stereotactic radiotherapy
Journal
Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420
Informations de publication
Date de publication:
01 10 2021
01 10 2021
Historique:
pubmed:
30
5
2021
medline:
6
10
2021
entrez:
29
5
2021
Statut:
ppublish
Résumé
To define efficacy and toxicity of Immunotherapy (IT) with stereotactic radiotherapy (SRT) including radiosurgery (RS) or hypofractionated SRT (HFSRT) for brain metastases (BM) from non-small cell lung cancer (NSCLC) in a multicentric retrospective study from AIRO (Italian Association of Radiotherapy and Clinical Oncology). NSCLC patients with BM receiving SRT + IT and treated in 19 Italian centers were analyzed and compared with a control group of patients treated with exclusive SRT. One hundred patients treated with SRT + IT and 50 patients treated with SRT-alone were included. Patients receiving SRT + IT had a longer intracranial Local Progression-Free Survival (iLPFS) (propensity score-adjusted P = .007). Among patients who, at the diagnosis of BM, received IT and had also extracranial progression (n = 24), IT administration after SRT was shown to be related to a better overall survival (OS) (P = .037). A multivariate analysis, non-adenocarcinoma histology, KPS = 70 and use of HFSRT were associated with a significantly worse survival (P = .019, P = .017 and P = .007 respectively). Time interval between SRT and IT ≤7 days (n = 90) was shown to be related to a longer OS if compared to SRT-IT interval >7 days (n = 10) (propensity score-adjusted P = .008). The combined treatment was well tolerated. No significant difference in terms of radionecrosis between SRT + IT patients and SRT-alone patients was observed. The time interval between SRT and IT had no impact on the toxicity rate. Combined SRT + IT was a safe approach, associated with a better iLPFS if compared to exclusive SRT.
Sections du résumé
BACKGROUND
To define efficacy and toxicity of Immunotherapy (IT) with stereotactic radiotherapy (SRT) including radiosurgery (RS) or hypofractionated SRT (HFSRT) for brain metastases (BM) from non-small cell lung cancer (NSCLC) in a multicentric retrospective study from AIRO (Italian Association of Radiotherapy and Clinical Oncology).
METHODS
NSCLC patients with BM receiving SRT + IT and treated in 19 Italian centers were analyzed and compared with a control group of patients treated with exclusive SRT.
RESULTS
One hundred patients treated with SRT + IT and 50 patients treated with SRT-alone were included. Patients receiving SRT + IT had a longer intracranial Local Progression-Free Survival (iLPFS) (propensity score-adjusted P = .007). Among patients who, at the diagnosis of BM, received IT and had also extracranial progression (n = 24), IT administration after SRT was shown to be related to a better overall survival (OS) (P = .037). A multivariate analysis, non-adenocarcinoma histology, KPS = 70 and use of HFSRT were associated with a significantly worse survival (P = .019, P = .017 and P = .007 respectively). Time interval between SRT and IT ≤7 days (n = 90) was shown to be related to a longer OS if compared to SRT-IT interval >7 days (n = 10) (propensity score-adjusted P = .008). The combined treatment was well tolerated. No significant difference in terms of radionecrosis between SRT + IT patients and SRT-alone patients was observed. The time interval between SRT and IT had no impact on the toxicity rate.
CONCLUSIONS
Combined SRT + IT was a safe approach, associated with a better iLPFS if compared to exclusive SRT.
Identifiants
pubmed: 34050669
pii: 6288399
doi: 10.1093/neuonc/noab129
pmc: PMC8485442
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1750-1764Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
JAMA Oncol. 2017 Jun 1;3(6):827-831
pubmed: 27892978
J Am Coll Cardiol. 2017 Jan 24;69(3):345-357
pubmed: 28104076
Science. 2018 Mar 23;359(6382):1366-1370
pubmed: 29567708
Semin Immunol. 2010 Jun;22(3):113-24
pubmed: 20403709
Neurooncol Pract. 2019 Sep;6(5):402-409
pubmed: 31555455
Clin Neurol Neurosurg. 2019 Apr;179:14-18
pubmed: 30784894
Radiat Oncol. 2020 Oct 27;15(1):245
pubmed: 33109224
JAMA Oncol. 2018 Aug 1;4(8):1123-1124
pubmed: 29327059
Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4):916-925
pubmed: 29485071
Lancet Oncol. 2016 Jul;17(7):976-983
pubmed: 27267608
N Engl J Med. 2017 Nov 16;377(20):1919-1929
pubmed: 28885881
J Neurosurg. 2019 Feb 15;132(2):512-517
pubmed: 30771783
Cancer J. 2017 Jan/Feb;23(1):32-39
pubmed: 28114252
Radiat Oncol. 2019 Jan 28;14(1):18
pubmed: 30691492
Lancet Oncol. 2015 Nov;16(15):e534-e542
pubmed: 26545842
JAMA. 2016 Jul 26;316(4):401-409
pubmed: 27458945
Int J Radiat Oncol Biol Phys. 2015 Jun 1;92(2):368-75
pubmed: 25754629
Int J Radiat Oncol Biol Phys. 2018 Jul 1;101(3):624-629
pubmed: 29678530
J Neurosurg. 2019 Jul 26;:1-8
pubmed: 31349225
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
Radiother Oncol. 2019 Jan;130:104-112
pubmed: 30241791
J Thorac Oncol. 2018 Apr;13(4):550-558
pubmed: 29378267
J Neurosurg. 2016 Jul;125(1):17-23
pubmed: 26544782
JAMA Oncol. 2015 Dec;1(9):1325-32
pubmed: 26270858
J Neurosurg. 2014 Dec;121 Suppl:16-25
pubmed: 25434933
J Neurooncol. 2017 Jun;133(2):331-338
pubmed: 28466250
Lancet Oncol. 2020 May;21(5):655-663
pubmed: 32251621
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Lancet Oncol. 2014 Apr;15(4):387-95
pubmed: 24621620
Clin Cancer Res. 2009 Sep 1;15(17):5379-88
pubmed: 19706802
J Neurosurg. 2018 Dec 1;129(Suppl1):86-94
pubmed: 30544291
Lancet. 2016 Apr 30;387(10030):1837-46
pubmed: 26970723
Lancet Oncol. 2015 Jun;16(6):e270-8
pubmed: 26065612
J Clin Oncol. 2011 Jan 10;29(2):134-41
pubmed: 21041710
Radiother Oncol. 2011 Mar;98(3):292-7
pubmed: 21316787
Blood. 2009 Jul 16;114(3):589-95
pubmed: 19349616
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
Int J Radiat Oncol Biol Phys. 2010 Jul 1;77(3):655-61
pubmed: 19942357
Clin Cancer Res. 2019 Mar 15;25(6):1709-1717
pubmed: 30413527
Lancet Oncol. 2015 Oct;16(13):e498-509
pubmed: 26433823
Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):1306-10
pubmed: 22208977
N Engl J Med. 2018 Aug 23;379(8):722-730
pubmed: 30134131